Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387289 | 0.82 | CYP1A2 (1.00) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL8864119 | 0.82 | CYP1A2 (0.72) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL224624 | 0.82 | CYP1A2 (0.72) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| Hydrochloric Acid SCHEMBL11333910 | 0.81 | CYP1A2 (0.96) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL3325578 | 0.80 | MAPT (0.54) | CYP1A2CYP2C19MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL11689824 | 0.79 | CYP1A2 (0.68) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL6284416 | 0.79 | CYP1A2 (0.68) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL11748979 | 0.79 | CYP1A2 (0.68) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL20413703 | 0.79 | CYP1A2 (0.68) | CYP1A2CYP2C19MAPK1LMNAPOLB | |
| SCHEMBL1143474 | 0.79 | CYP1A2 (0.68) | CYP1A2CYP2C19MAPK1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2755962-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-6949648-B2 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1270572-A1 | CONDENSED PYRAZOLE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | CYP1A2 72/4885CYP2C19 113/4885MAPK1 3876/4885 |
| US-20030187014-A1 | Condensed pyrazole derivatives, process for producing the same and use thereof | PTGS1, PTGIS, IL5 | CYP1A2 113/4885CYP2C19 58/4885MAPK1 877/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | CYP1A2 72/4885CYP2C19 113/4885MAPK1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.